Stocks · News reference
Clearmind Medicine Advances Its IP Portfolio With Publication In U.S. Of Its Patent Application For Novel Combination Of 3,4-Methylenedioxymethamphetamine And N-Acylethanolamines To Treat Post-Traumatic Stress Disorder
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 24, 2026, 12:07 PM
- Checked
- Aug 24, 2026, 1:28 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Clearmind Medicine Makes Clinical Progress in Alcohol Addiction Treatment Trial
Clearmind Medicine advances the CMND-100 clinical trial for alcohol use disorder to Parts B and C following positive Phase A safety data.
Read original at benzingaClearmind Medicine Says DSMB Unanimously Approved Advancing Phase 1/2 Trial Of CMND-100 To Parts B And C In Alcohol Use Disorder Patients And Healthy Participants
Read original at benzinga